Meeting
2022 ASCO Annual Meeting
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
Authors
Sung Jun Ma
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Sung Jun Ma , Jasmin Gill , Keerti Yendamuri , Brian Yu , Song Yao , Oluwadamilola Temilade Oladeru , Anurag K. Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 529)
DOI
10.1200/JCO.2022.40.16_suppl.529
Abstract #
529
Poster Bd #
301
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Association of the presence of estrogen and progesterone receptors in uterine carcinosarcoma with improved survival and increased immunogenicity.
First Author: Nathaniel L. Jones
Poster
2020 ASCO Virtual Scientific Program
Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.
First Author: Mansoor Raza Mirza
Poster
2017 ASCO Annual Meeting
Ki67 as a prognostic factor in low grade serous ovarian cancer (LGSOC): A retrospective analysis of the Tumor Bank Ovarian Cancer (TOC).
First Author: Jalid Sehouli
Poster
2016 ASCO Annual Meeting
Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus <1%).
First Author: Sangeetha Meda Reddy